ILCS2025 | Lung Summit

SELECT FROM MENU

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

by PEAK Medicals | 26 September 2025

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES Noemí Reguart (Spain)  } 27 min Download...

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

by PEAK Medicals | 26 September 2025

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC? AMIVANTAMAB + LAZERTINIB Xiuning Le (USA) Osimertinib + Chemotherapy Tom Newsom-Davis (UK)  } 30 min Download...

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

by PEAK Medicals | 26 September 2025

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET Stephanie Saw (Singapore)  } 26 min Download...

TARGETING EGFR AND ALK IN NSCLC

TARGETING EGFR AND ALK IN NSCLC

by PEAK Medicals | 26 September 2025

TARGETING EGFR AND ALK IN NSCLC Tom John (Australia)  } 26 min Download...

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

by PEAK Medicals | 26 September 2025

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS Marius Ilié (France)  } 24 min Download...

« Older Entries

Next Entries »